Answers are grounded in this paper and cite their sources.
In Brief Purpose: The purpose of this study was to compare visual outcomes after treatment with intravitreal antivascular endothelial growth factor (anti-VEGF) injection or photodynamic therapy (PDT) in patients with myopic choroidal neovascularization (CNV). Methods: One hundred and forty-two eyes of 128 consecutive patients treated with anti-VEGF (ranibizumab or bevacizumab) and/or PDT for myopic choroidal neovascularization were retrospectively reviewed. Patients were categorized into 3 groups: PDT (51 eyes), anti-VEGF (63 eyes), and a combination group (PDT with anti-VEGF) (28 eyes). Corrected visual acuity values at baseline and 3, 6, 9, and 12 months after treatment were compared. Results: The anti-VEGF group showed significant postoperative improvement in visual acuity compared with the PDT and combination groups (P = 0.01 and 0.04, respectively). The anti-VEGF group demonstrated visual improvement from baseline at every follow-up visit after treatment (P = 0.04, 0.02, 0.01, and 0.002, respectively). The anti-VEGF group showed visual improvement (Snellen equivalent) from 0.57 logarithm of the minimum angle of resolution (0.27) to 0.33 logarithm of the minimum angle of resolution (0.47) (P = 0.01). Furthermore, 98.4% of patients in the anti-VEGF group and 92.8% of those in the combination group lost <15 letters from baseline visual acuity compared with 72.6% in the PDT group (P = 0.001 and 0.02, respectively). In the anti-VEGF group, 39.7% of patients improved from baseline by 15 or more letters compared with 17.7% in the PDT group (P = 0.02) and 21.4% in the combination group (P = 0.07). Conclusion: Intravitreal anti-VEGF injection is superior to PDT alone or a combination of PDT with anti-VEGF for treating myopic choroidal neovascularization. Intravitreal anti-VEGF injection was superior to photodynamic therapy (PDT), either alone or in combination, for treatment of myopic choroidal neovascularization. Eyes without previous PDT treatment demonstrated better visual improvement after intravitreal antivascular endothelial growth factor (anti-VEGF) injections than did eyes previously treated with PDT. Combination of anti-VEGF therapy with PDT may reduce the visual acuity improvement achieved with anti-VEGF alone.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: